Resultados de la búsqueda 71-80 of 21505 for Treatment

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer.

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6- ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer.

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    (Z)-Endoxifen For The Treatment Of Premenopausal Women With ER+/HER2- Breast Cancer. Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. This ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... treatment, post-treatment and (when available) post-mortem soft tissue sarcoma (STS) tissue and tissue data with an emphasis on STSs occurring in younger ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients may receive a single dose to a liver lobe or segmental treatment delivered as a sequence of treatments approximately 30-90 days apart. The ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients may receive a single dose to a liver lobe or segmental treatment delivered as a sequence of treatments approximately 30-90 days apart. The ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients may receive a single dose to a liver lobe or segmental treatment delivered as a sequence of treatments approximately 30-90 days apart. The ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients may receive a single dose to a liver lobe or segmental treatment delivered as a sequence of treatments approximately 30-90 days apart. The ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Personalized Neoantigen Peptide-Based Vaccine In Combination With Pembrolizumab For Treatment Of Advanced Solid Tumors. Jacksonville, Fla. This phase I/II ...